½ÃÀ庸°í¼­
»óǰÄÚµå
1274655

¼¼°èÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå º¸°í¼­(2023³â)

Nuclear Medicine Diagnostics Global Market Report 2023

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Business Research Company | ÆäÀÌÁö Á¤º¸: ¿µ¹® 250 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇÙÀÇÇÐ Áø´Ü ¼¼°è ½ÃÀåÀº 2022³â 59¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2023³â 65¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ¿¬Æò±Õ 11.2% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ÀüÀïÀº Àû¾îµµ ´Ü±âÀûÀ¸·Î´Â Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¼¼°è °æÁ¦ ȸº¹ °¡´É¼ºÀ» È¥¶õ½º·´°Ô ¸¸µé¾ú½À´Ï´Ù. ¾ç±¹ °£ÀÇ ÀüÀïÀº ¿©·¯ ±¹°¡¿¡ ´ëÇÑ °æÁ¦ Á¦Àç, »óǰ °¡°Ý »ó½Â, °ø±Þ¸Á È¥¶õÀ¸·Î À̾îÁ® Àüü »óǰ°ú ¼­ºñ½º¿¡ ´ëÇÑ ÀÎÇ÷¹À̼ÇÀ» À¯¹ßÇÏ°í ¼¼°è ¸¹Àº ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÇÙÀÇÇÐ Áø´Ü ½ÃÀåÀº ¿¬Æò±Õ 10.5%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2027³â 98¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â 2022³â ÇÙÀÇÇÐ Áø´Ü ½ÃÀå¿¡¼­ °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀÌ µÉ °ÍÀÔ´Ï´Ù. ÇÙÀÇÇÐ Áø´Ü ½ÃÀå º¸°í¼­ÀÇ ´ë»ó Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ¼­À¯·´, Áßµ¿ ¹× µ¿À¯·´, ºÏ¹Ì, ³²¹Ì, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù.

ÇÙÀÇÇÐ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÇâÈÄ ÇÙÀÇÇÐ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÙÀÇÇÐÀº ü³»ÀÇ ¹æ»ç¼º ¹°ÁúÀ» »ç¿ëÇÏ¿© Áúº´À» Áø´ÜÇϰųª Áúº´À̳ª ¼Õ»óµÈ Àå±â³ª Á¶Á÷À» Ç¥ÀûÀ¸·Î »ï¾Æ Á¦°Å(Ä¡·á)ÇÏ´Â °ÍÀÔ´Ï´Ù. ÇÙÀÇÇÐÀÇ Áø´ÜÀû ¿ëµµ´Â ÁÖ·Î ¹æ»ç¼± Ä¡·á ¹× ±âŸ »ý¸íÀ» À§ÇùÇÏ´Â Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ÇÙÀÇÇÐ Áø´ÜÀº Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°í, Ä¡·á °áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ´Â µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù ¿µ±¹¿¡ º»ºÎ¸¦ µÐ ¿øÀÚ·Â ÃßÁø ±¹Á¦±â±¸ÀÎ ¼¼°è¿øÀÚ·ÂÇùȸ°¡ ¹ßÇ¥ÇÑ ÇÙÀÇÇÐ Áø´Ü º¸°í¼­¿¡ µû¸£¸é, ÇÙÀÇÇÐ ¿¬°£ Ä¡·á °Ç¼ö´Â 4,000¸¸ °ÇÀ» ³Ñ¾î¼¹°í, ¹æ»ç¼º µ¿À§¿ø¼Ò Çʿ䷮Àº ¸Å³â ÃÖ´ë 5%ÀÇ ºñÀ²·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á¿ë ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ ÀÌ¿ëÇÑ Ä¡·áÀÇ 90%´Â ¼¼°è 1¸¸ °³ ÀÌ»óÀÇ º´¿ø¿¡¼­ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÇÙÀÇÇÐ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÇÙÀÇÇÐ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå Æ¯Â¡

Á¦3Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

  • COVID-19¿¡ ÀÇÇÑ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ
  • ¿ìÅ©¶óÀ̳ª¡¤·¯½Ã¾Æ ÀüÀïÀÌ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • °íÀÎÇ÷¹À̼ÇÀÌ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ±Ô¸ð¿Í ¼ºÀå

  • ¼¼°èÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ½ÇÀû, 2017-2022³â
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¼¼°èÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ¿¹Ãø, 2022-2027³â, 2032³â
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

Á¦6Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • SPECT ¹æ»ç¼º ÀǾàǰ
  • PET ¹æ»ç¼º ÀǾàǰ
  • ¼¼°èÀÇÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ½ÉÀ庴ÇÐ
  • °©»ó¼±
  • ½Å°æ³»°ú
  • Á¾¾çÇÐ
  • ±âŸ ¿ëµµ
  • ¼¼°èÀÇÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • º´¿ø ¹× Áø´Ü¼¾ÅÍ
  • ¿¬±¸±â°ü

Á¦7Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå : Áö¿ª ¹× ±¹°¡º° ºÐ¼®

  • ¼¼°èÀÇÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, Áö¿ªº°, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ¼¼°èÀÇÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ±¹°¡º°, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • Áö¿ª Á¤º¸, COVID-19ÀÇ ¿µÇâ, ½ÃÀå Á¤º¸, ¹è°æ Á¤º¸, Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê, ±ÔÁ¦, ±ÔÁ¦±â°ü, ÁÖ¿ä ´Üü, °ú¼¼¾×, ¹ýÀμ¼ ±¸Á¶, ÅõÀÚ, ÁÖ¿ä ±â¾÷
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦9Àå Áß±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • Áß±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • Áß±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • Áß±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦10Àå ÀεµÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ÀεµÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ÀεµÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦11Àå ÀϺ»ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ÀϺ»ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ÀϺ»ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦12Àå È£ÁÖÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • È£ÁÖÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • È£ÁÖÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦13Àå Àεµ³×½Ã¾ÆÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • Àεµ³×½Ã¾ÆÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • Àεµ³×½Ã¾ÆÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦14Àå Çѱ¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • Çѱ¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • Çѱ¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦15Àå ¼­À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ¼­À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • ¼­À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ¼­À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦16Àå ¿µ±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ¿µ±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ¿µ±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦17Àå µ¶ÀÏÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • µ¶ÀÏÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • µ¶ÀÏÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦18Àå ÇÁ¶û½ºÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ÇÁ¶û½ºÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ÇÁ¶û½ºÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦19Àå µ¿À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • µ¿À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • µ¿À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • µ¿À¯·´ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦20Àå ·¯½Ã¾ÆÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ·¯½Ã¾ÆÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ·¯½Ã¾ÆÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦21Àå ºÏ¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ºÏ¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • ºÏ¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ºÏ¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦22Àå ¹Ì±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ¹Ì±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • ¹Ì±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ¹Ì±¹ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦23Àå ³²¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ³²¹ÌÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • ³²¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ³²¹ÌÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦24Àå ºê¶óÁúÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ºê¶óÁúÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ºê¶óÁúÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦25Àå Áßµ¿ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • Áßµ¿ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • Áßµ¿ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • Áßµ¿ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦26Àå ¾ÆÇÁ¸®Ä«ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå

  • ¾ÆÇÁ¸®Ä«ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °³¿ä
  • ¾ÆÇÁ¸®Ä«ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F
  • ¾ÆÇÁ¸®Ä«ÀÇ ÇÙÀÇÇÐ Áø´Ü ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ½ÇÀû ¹× ¿¹Ãø, 2017-2022, 2022-2027F, 2032F

Á¦27Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

  • ÇÙÀÇÇÐ Áø´Ü ½ÃÀå °æÀï ±¸µµ
  • ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ±â¾÷ °³¿ä
    • Cardinal Health Inc.
    • GE HealthCare Technologies Inc.
    • Lantheus
    • Bayer AG
    • Bracco Diagnostic Inc.

Á¦28Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦29Àå ÇÙÀÇÇÐ Áø´Ü ½ÃÀå Àü¸Á°ú °¡´É¼º ºÐ¼®

Á¦30Àå ºÎ·Ï

LSH 23.05.25

“Nuclear Medicine Diagnostics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The nuclear medicine diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
  • 2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
  • 3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
  • Companies Mentioned: Cardinal Health Inc.; GE HealthCare Technologies Inc.; Lantheus; Bayer AG; Bracco Diagnostic Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the nuclear medicine diagnostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Lantheus, Bayer AG, Bracco Diagnostic Inc., NorthStar Medical Radioisotopes LLC, Eckert & Ziegler, Jubilant DraxImage Inc., PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., SHINE Medical Technologies LLC, Global Medical Solutions LLC, Bracco Imaging SPA, Advanced Accelerator Applications, IBA Molecular Imaging, Mallinckrodt PLC., and Curium Pharma.

The global nuclear medicine diagnostics market is expected to grow from $5.92 billion in 2022 to $6.58 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nuclear medicine diagnostics market is expected to grow to $9.82 billion in 2027 at a CAGR of 10.5%.

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). Nuclear medicine includes the use of radioactive drugs for research, therapeutic, and diagnostic purposes. Radioactive tracers are used in diagnostic nuclear medicine to visualize and/or measure the overall or local function of an organ.

North America was the largest region in the nuclear medicine diagnostics market in 2022. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of nuclear medicine diagnostics are SPECT radiopharmaceuticals and PET radiopharmaceuticals. A single-photon emission computerized tomography (SPECT) Radiopharmaceuticals refer to gamma-ray tomographic imaging methods that are used in nuclear medicine. The various applications involved are cardiology, thyroid, neurology, oncology and others and the end-users include hospitals and diagnostic centers and research institutes.

The increasing demand for nuclear medicine diagnostics is expected to propel the growth of the nuclear medicine diagnostics market going forward. Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). The diagnostic uses of nuclear medicine are primarily in radiation and other life-taking treatments. The demand for nuclear medicine diagnostics is increasing due to benefits such as accurate results and better treatment decision making. For instance, in April 2022, according to a report published on nuclear medicine diagnostics by the World Nuclear Association, a UK-based international organization that promotes nuclear power, the annual number of nuclear medicine treatments exceeds 40 million, and the need for radioisotopes is rising at a rate of up to 5% every year. Also, 90% of the procedures involving radioisotopes in medicine take place in more than 10,000 hospitals used worldwide. Hence, increasing demand for nuclear medicine diagnostics is expected to propel the growth of the nuclear medicine diagnostics market.

Innovative product development is a key trend gaining popularity in the nuclear medicine diagnostics market. Major companies operating in the nuclear medicine diagnostics market are undergoing the development of innovative products to strengthen their position in the market. For instance, in December 2020, the Food and Drug Administration (FDA), a US-based association responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, and biological products, approved 68Gallium PSMA-11 (Ga 68 PSMA-11) - the first drug for PET (positron emission tomography) imaging men with prostate cancer, the third most frequent type of cancer in the United States, often have PSMA-positive lesion. This certification is anticipated to raise interest in 68Gallium, a PET imaging isotope that is currently in short supply.

In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific and industrial use acquired Tecnonuclear SA for an undisclosed amount. This acquisition will enable Eckert & Ziegler to expand essential healthcare services in Brazil and throughout South America. Tecnonuclear SA is an Argentina-based nuclear medicine specialist company.

The countries covered in the nuclear medicine diagnostics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Diagnostics Market Characteristics

3. Nuclear Medicine Diagnostics Market Trends And Strategies

4. Nuclear Medicine Diagnostics Market - Macro Economic Scenario

  • 4.1. COVID-19 Impact On Nuclear Medicine Diagnostics Market
  • 4.2. Ukraine-Russia War Impact On Nuclear Medicine Diagnostics Market
  • 4.3. Impact Of High Inflation On Nuclear Medicine Diagnostics Market

5. Nuclear Medicine Diagnostics Market Size And Growth

  • 5.1. Global Nuclear Medicine Diagnostics Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Nuclear Medicine Diagnostics Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Nuclear Medicine Diagnostics Market Segmentation

  • 6.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • SPECT Radiopharmaceuticals
  • PET Radiopharmaceuticals
  • 6.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Cardiology
  • Thyroid
  • Neurology
  • Oncology
  • Other Applications
  • 6.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospitals And Diagnostic Centers
  • Research Institutes

7. Nuclear Medicine Diagnostics Market Regional And Country Analysis

  • 7.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Nuclear Medicine Diagnostics Market

  • 8.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Nuclear Medicine Diagnostics Market

  • 9.1. China Nuclear Medicine Diagnostics Market Overview
  • 9.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Nuclear Medicine Diagnostics Market

  • 10.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Nuclear Medicine Diagnostics Market

  • 11.1. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Nuclear Medicine Diagnostics Market

  • 12.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Nuclear Medicine Diagnostics Market

  • 13.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Nuclear Medicine Diagnostics Market

  • 14.1. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Nuclear Medicine Diagnostics Market

  • 15.1. Western Europe Nuclear Medicine Diagnostics Market Overview
  • 15.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Nuclear Medicine Diagnostics Market

  • 16.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Nuclear Medicine Diagnostics Market

  • 17.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Nuclear Medicine Diagnostics Market

  • 18.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Nuclear Medicine Diagnostics Market

  • 19.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
  • 19.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Nuclear Medicine Diagnostics Market

  • 20.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Nuclear Medicine Diagnostics Market

  • 21.1. North America Nuclear Medicine Diagnostics Market Overview
  • 21.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Nuclear Medicine Diagnostics Market

  • 22.1. USA Nuclear Medicine Diagnostics Market Overview
  • 22.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Nuclear Medicine Diagnostics Market

  • 23.1. South America Nuclear Medicine Diagnostics Market Overview
  • 23.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Nuclear Medicine Diagnostics Market

  • 24.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Nuclear Medicine Diagnostics Market

  • 25.1. Middle East Nuclear Medicine Diagnostics Market Overview
  • 25.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Nuclear Medicine Diagnostics Market

  • 26.1. Africa Nuclear Medicine Diagnostics Market Overview
  • 26.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

  • 27.1. Nuclear Medicine Diagnostics Market Competitive Landscape
  • 27.2. Nuclear Medicine Diagnostics Market Company Profiles
    • 27.2.1. Cardinal Health Inc.
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. GE HealthCare Technologies Inc.
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Lantheus
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Bayer AG
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Bracco Diagnostic Inc.
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

29. Nuclear Medicine Diagnostics Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Historic And Forecast Inflation Rates
  • 30.4. Research Inquiries
  • 30.5. The Business Research Company
  • 30.6. Copyright And Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦